Aspirin-Triggered Lipoxin and Resolvin E1 Modulate Vascular Smooth Muscle Phenotype and Correlate with Peripheral Atherosclerosis

Abstract

Atherosclerosis is a chronic inflammatory disease of the vessel wall. Recent evidence suggests that chronic vascular inflammation ensues as an imbalance between pro-and anti-inflammatory mediators. Recently identified lipid mediators (eg, lipoxins and resolvins) play active roles in promoting the resolution of inflammation. Alterations in vascular smooth muscle cell (VSMC) phenotype, which manifest as a loss of contractile protein expression and increased proliferation and migration, are prominent mechanistic features of both atherosclerosis and restenosis following various interventions (eg, angioplasty and bypass grafting). We sought to determine whether human atherosclerosis is associated with a "resolution deficit" and whether lipoxins and resolvins influence VSMC phenotype. Here we report that plasma levels of aspirin-triggered lipoxin are significantly lower in patients with symptomatic peripheral artery disease than in healthy volunteers. Both aspirintriggered lipoxin and resolvin E1 block platelet-derived growth factor-stimulated migration of human saphenous vein SMCs and decrease phosphorylation of the platelet-derived growth factor receptor-␤. Importantly, receptors for aspirin-triggered lipoxin and resolvin E1 (ALX and ChemR23, respectively) were identified in human VSMCs. Overall, these results demonstrate that stimulatory lipid mediators confer a protective phenotypic switch in VSMCs and elucidate new functions for these mediators in the regulation of SMC biology. These results also suggest that peripheral artery disease is associated with an inflammation-resolution deficit and highlight a potential therapeutic opportunity for the regulation of vascular injury responses. (Am J Pathol

Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators

“…This is of general relevance to inflammatory diseases in humans because it is sometimes difficult to obtain temporal changes in LM profiles during disease states and their resolution. 36 Nonetheless, LXA 4 levels increase during resolution of glomerulonephritis, 37 and PD1 levels are diminished in exhaled breath condensates from asthmatics. 38 Systematic mapping of cellular trafficking in a murine model of self-limited acute inflammation demonstrated that mononuclear cell accumulation at the site of inflammation occurs as part of the events that lead to the onset of resolution.…”

Bioactive products formed in humans from fish oils

“…There are few data attesting to their formation in humans based on rigorous mass spectrometric methodology. Most clinical investigations reporting the formation of SPMs rely on immunoassays ( 21 ) or MS without synthetic internal standards structurally similar to the SPMs under investigation (22)(23)(24)(25)(26)(27)(29)(30)(31)(32), often in ex vivo stimulated systems ( 17,(33)(34)(35)(36).…”

Biomechanical regulation of vascular smooth muscle cell functions: from in vitro to in vivo understanding

“…The abnormal proliferation and migration of vascular smooth muscle cell (VSMC) are key components of various vascular diseases, including hypertension, atherosclerosis and vascular stenosis after vessel transplant [1][2][3][4]. In addition, VSMC apoptosis is one of the dominant factors that induce plaque vulnerability in atherosclerosis [5,6].…”